Call Us: 954-929-4814
American Metabolic Laboratories may be the only laboratory performing QUANTITATIVE HCG URINE TESTING (HCG-U). This test has the analytical detection level of 0.4 mlU/mL, same as the HCG-IMM blood test.
The inclusion of HCG-U will eliminate the possibility of a false positive caused by a non-specific heterophile serum test reaction. The HCG Urine may further confirm the results of the Serum HCG IMM. A positive HCG-U test is deemed essential and confirmatory criterion of the biological reality of the true presence of the hormone. A positive HCG-IMM and HCG-U may strongly suggest the reality of a developing or existing tumor. However, the IMM test enumerates the amount of total, and all other molecular forms of HCG in the blood, including tumor generated intact, beta and beta fragments, and pituitary HCG-L species. Neither HCG-U, nor HCG-IMM alone can yield satisfactory results.
HCG only in the urine of females and males may be present as a result of age promoted developing or existing gonadal insufficiency. Generally, postmenopausal women and aging men experience a reduced or even seized production of estradiol, progesterone, or testosterone respectively. The immediate biochemical response is the production of large quantities of lutenizing hormone (LH) and follicle stimulating hormone (FSH) in both genders to stimulate the gonads to produce the sex hormones. In this pituitary rush, the aberrant HCG-Like (HCG-L) hormone is produced, in rather small quantities. This molecular hormone species could be present in the urine of such individuals. The reason why it may show up in the first morning urine and not in the blood is that the minute quantities produced over night are collected in several hours of time in relatively small volume of urine as compared to several liters of blood. Thus in the blood, the HCG/HCG-L becomes diluted to beyond measurable amounts. Even though the HCG-L species are not tumor generated, it has HCG hormonal activity estimated to be approximately one-half of the tumor or the pregnancy hormone. In order to eliminate the production of the aberrant HCG-L, hormone replacement therapy, e.g. prometrium has been recommended. An elevated FSH level will indicate a good probability of HCG-L pituitary synthesis.
For HCG test result interpretation, experts recommend a positive agreement of two different testing methodologies. American Metabolic Laboratories are simultaneously performing two HCG tests: Serum and Urine HCG-IMM (chemiluminescence assay).
Normal Value is less than 1.1 mIU/mL. Gray zone is 1.1 - 3.8 mIU/mL.
How is our test different from the Navarro Test?
Dr. Navarro was the first individual testing for cancer with his HCG Urine test. We very much appreciate his pioneering work. However, his technology is much outdated and may not distinguish between HCG, TSH, FSH, and LH in the urine sample. Therefore, the results may reflect the sum of all those four hormones in the urine. The Navarro normal results are below 50,000 mIU/mL, i.e. 50 IU/L. Would you not want to know what is between 0 and 49 negative range? Most likely the sum of FSH, LH, TSH, and HCG. The human pituitary gland secretes large quantities of the messengers FSH, LH in Peri-Post menopausal women and older men. Hence, it may well be these hormones present in the 0 to 49 zone, and not HCG.
Our HCG Urine Quantitative test is specific for the HCG hormone, no other hormone. This is to say, unlike Navarro's test and over the counter pregnancy tests, our test has no possible cross reactivity with TSH, FSH, and LH hormones. Furthermore, the analytical sensitivity of our HCG test is 0.4 mIU/mL, not 50,000. Our normal results are less than 1.0 mIU/mL, i.e., several thousand times lower. Most cancer patients and those who may be in the process of developing cancer will yield less than 5 mIU/mL. Therefore, the Navarro test may miss most early developing or existing cancers.
Values obtained with different assay methods should not be used interchangeably.
Neither the HCG urine nor serum alone or together is sufficient to detect or follow a cancer disease in process